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Abstract 
 
Massie, Michael Todd. M.S., Department of Physics, Wright State University, 
2010. Respiratory-Gated IMRT Quality Assurance with Motion in Two 
Dimensions. 
 
 
 
 Intensity modulated radiation therapy (IMRT) plans can be further 
customized to each patient with the use of a four-dimensional (4D) respiratory-
gated computed tomography (CT), with time being the fourth dimension. The 4D 
respiratory-gated CT allows for the internal margin (IM), the expansion of the 
tumor volume that accounts for physiologic motions, to be addressed in the 
treatment planning process and no longer assumes that the treatments will be 
delivered to a fixed or rigid patient anatomy. Delivering the IMRT plan with a 
gated technique limits the treatment to a duty cycle when the target motion is at a 
minimum. 
 The goal of this project is to study respiratory-gated IMRT quality 
assurance (QA) results for tumor motion in two dimensions and develop a 
guideline for acceptable limits on tumor motion and field size.  Respiratory-gated 
IMRT QA was performed for four field sizes and varying amounts of motion with a 
fixed duty cycle using Sun Nuclearʼs MapCHECK and MotionSIM XY/4D 
products. The treated and planned dose planes were compared and errors were 
evaluated using standard acceptance conditions. 
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1. Introduction 
The American Cancer Society estimated that the number of diagnosed 
lung cancers cases in 2009 would reach 219,440. This accounts for 15% of all 
cancer diagnoses. The report also estimates that lung cancer will result in 
159,390 deaths in 2009 and about 28% of all deaths from cancer. The treatment 
options for lung cancer include surgery, radiation therapy, chemotherapy, and 
targeted biological therapies. The location, type, and stage of the cancer 
determine the treatment method. Advances in surgical techniques and the use of 
combined therapies have increased the 1-year survival rate from 35% to 41% 
over a twenty-year period. The 5-year survival rate for the combination of all 
stages of the cancer remains low at 15% (American Cancer Society, 2009). 
For non-small cell lung cancer (NSCLC) patients, where surgery may not 
be an option, radiation therapy is the main course of treatment. Machtay et al. 
reviewed 1,290 patients to determine a link between the Biological Equivalent 
Dose (BED) and outcomes of patients with nonoperative NSCLC when treated 
with radiation and chemotherapy.  The results showed an 18% decrease in the 
risk of death for every 10-Gy increase in BED (Machtay et al., 2005). In order to 
escalate the tumor dose to these levels and control the complications that 
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result from increased dose to normal tissue, intensity-modulated radiation 
therapy (IMRT) is used to deliver a dose distribution that conforms as closely as 
possible to the target and reduce the dose to the normal structures.  
 The IMRT treatment delivers a nonuniform fluence through several beam 
positions to optimize a conformal dose distribution to the target. Small field 
segments that are delivered by the multileaf collimator (MLC) generate the 
nonuniform fluence. MLCs are traditionally used in shaping the beam apertures, 
but can be programmed to deliver IMRT by the “step and shoot” or “sliding 
window” techniques. The “step and shoot” method divides the treatment field into 
a set of uniform intensity subfields that are delivered in a stack arrangement one 
at a time. The linear accelerator is turned off as the MLCs move into position for 
the next subfield. The treatment area of the subfields can overlap and the 
intensity-modulation is seen in the composite of the fields. In the “slide window” 
method, the opposing leaves sweep across the treatment area with a different 
velocity as a function of time to create the intensity-modulation.  One important 
issue with lung IMRT is the intrafraction motion. Intrafraction motion is motion 
that occurs during a single treatment and can be caused by respiratory motion, 
cardiac motion, and swallowing. Respiratory motion can cause tumor motion in 
the lung to move in any direction and can range several centimeters. The 
magnitude of the intrafraction motion generally cannot be predicted by tumor 
location, size, and pulmonary function (Keall et al., 2006). 
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 Conventional imaging techniques of the lung, such as x-rays and 3D-CT, 
only image a fraction of a patients breathing cycle and cause motion artifacts. 
These artifacts distort the tumor volume and can cause errors in tumor location. 
Because the complete range of tumor motion is not visualized in the images, a 
uniform margin of 7 mm-10 mm was traditionally added to the target to account 
for motion. This less than ideal practice often includes more normal tissue in the 
treatment than is necessary. Because a lung tumor can have as much as 3 cm of 
motion, this practice can also lead to tumor misses (Khan, 2007). Image-guided 
radiation therapy (IGRT) can be used to manage the intrafraction motion caused 
by the respiratory cycle. Four-dimensional CT (4-D CT) images allow the 
treatment planner to measure the tumor motion in all directions and track the 
tumor motion through phases of the breathing cycle. A 4-D CT can use as many 
as 1,500 CT slices to reconstruct multiple CT volumes that are used to divide the 
breathing cycle into phases. The 4-D CT can then be used to more accurately 
determine the internal margin (IM) needed to account for the motion.  
The ideal target volume in the lung would remain stationary during 
treatment. Any amount of IM that is added around a moving tumor to insure it 
remains within the treatment field only increases the risk of normal tissue 
complications. One method to decrease the IM is to use gated radiotherapy. 
During a gated therapy treatment, the radiation beam is synchronized with the 
breathing cycle. The beam is set to turn on only during chosen phases of the 
breathing cycle where the amount of motion is small (Khan, 2010). 
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Because the radiation beam is turning on and off, gated IMRT with a duty 
cycle of 30% to 50% can lead to a 4 to 15 fold increase in the delivery time over 
conventional treatments (Wagman et al., 2001). Extending the delivery time can 
cause the patient to become uncomfortable and introduce additional patient 
motion. Increasing the duty cycle reduces the delivery time and results in residual 
motion. Residual motion is the tumor motion that still remains in the duty cycle of 
a gated treatment. The combination of the residual tumor motion and the 
movement of the MLC, which controls the fluence delivery, is known as interplay. 
Interplay can introduce distortions in the desired dose distribution (Chen et al., 
2009). 
The primary goal of respiratory-gated IMRT is to accurately deliver the 
prescribed dose to a moving target while keeping the dose to the normal tissue 
and critical structures as low as possible. The motion of the tumor in a non-
uniform dose distribution can cause a dose blurring effect. This effect can cause 
the tumor to receive a lower dose and can be significant at the edges of the 
tumor. The effect can also influence the dose to normal tissue as the high dose 
gradient between the normal tissue and the tumor volume is blurred. A study by 
Chen et al. asked the question “how much residual motion is acceptable during 
gated IMRT?” The study used different size gating windows with motion of 0.5 cm 
to 3 cm in only one dimension for various IMRT delivery techniques and 
recommended that a residual motion of 0.5 cm should be used for the selection 
of gating windows (Chen et al., 2009).  
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An IMRT plan requires additional support from physics, physician, dosimetrist, 
and therapist. It often takes 4-5 days to develop a treatment plan after the initial 
simulation. Adding respiratory-gating to the plan can increase the workload by 
several hours (Keall et al., 2006). After the plan is completed, IMRT QA is 
performed before the first treatment is delivered. The IMRT QA confirms that the 
treatment plan delivers the anticipated dose distribution. The residual motion of a 
gated treatment can jeopardize the chances of a plan passing QA. A plan that 
fails QA cannot be used for treatment and must start the treatment plan process 
over. This not only delays the treatment, but changes must be made to the plan 
to make it acceptable for treatment. This may include changes in the margins, 
normal tissue constraints, prescription, beam arrangement, gating window, or 
delivery technique.  
 The goal of this study is to develop a reference guide to prevent treatment 
delays and wasted staff hours on gated-IMRT plans that are unlikely to pass 
IMRT QA. This study will use the IMRT quality assurance (QA) results from four 
respiratory-gated treatment plans to develop a baseline for acceptable limits on 
tumor motion and field size. The four plans represent cases for small, medium, 
large, and split field sizes. IMRT QA was performed for each plan using varying 
amounts of tumor motion in one and two dimensions. A beam on period 
frequently used in our clinic, the 30% to 70% phase, was selected for all the 
measurements. The QA was performed with SunNuclearʼs MapCHECK and 
MotionSIM XY/4D products. The MapCHECK, a 2-dimensional diode array, was 
 
6 
mounted onto the MotionSIM XY/4D motorized device that allows one to program 
a motion kernel and simulate the patientʼs breathing cycle. Plans were accepted 
if at least 90% of the points met an acceptance criterion.  
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2. Background and Theory 
X-Ray Production 
 Bremsstrahlung and characteristic x-rays are the two methods that 
generate x-rays. The bremsstrahlung or “braking radiation” process is an 
interaction between a fast moving electron and a nucleus. As the high-speed 
electron approaches the nucleus, Coulomb forces cause the electron to deflect or 
accelerate. As a result, the electron sufferers from all or part of itʼs kinetic energy 
being transformed into electromagnetic radiation known as a bremsstrahlung 
photon.   
 
Figure 2.1 Diagram showing the bremsstrahlung process (Khan, 2010).
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Because the bremsstrahlung photon can receive all or part of the 
electronʼs energy, the bremsstrahlung process produces a heterogeneous photon
energy spectrum. The incident energy of the electrons determines the direction of 
the emitted photon. Electron energies below 100 keV produce photons that are 
emitted in all directions. As the energy of the electrons increase, the emitted 
photons begin to be more forward dominant. Figure 2.2 shows the spatial 
distribution of x-rays around a target for a given electron energy. 
 
 
 
Figure 2.2 Spatial distribution of x-rays for a given electron energy (Khan, 2010). 
 
 The target is the source of nuclei for interactions with the high-speed 
electrons.  Because the probability of bremsstrahlung production varies with the 
square of the atomic number (Z2) for the target, most targets are made of high Z 
material such as tungsten (Z=74). The forward direction of bremsstrahlung 
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photons in the megavoltage (MV) range allow for the use of a transmission-type 
target. The ratio of the output energy of the x-rays to the input energy deposited 
by the electrons defines the efficiency of the bremsstrahlung process and is given 
by: 
€ 
Efficiency = 9 ×10−10ZV
 
where Z is the atomic number and V is the tube voltage in volts. The equation is 
limited to tube voltages below a few MV (Khan, 2010). For low energy electrons, 
the process is inefficient (1%) and most of the input energy is converted to heat 
(99%). As the electron energy increases, the bremsstrahlung process can 
increase to 95% in efficiency.  
 High-speed electrons interacting with the atoms of the target material can 
also produce characteristic x-rays. Characteristic x-rays are formed when an 
electron has enough kinetic energy to eject an orbital electron from the target 
material. The kinetic energy needed to eject the orbital electron needs to be 
greater than the binding energy for that orbital shell. The kinetic energy that the 
primary electron will leave the collision with is reduced by the amount deposited 
to the orbital electron.  The ejected orbital electron will leave the ionized atom 
with the amount of energy received by the incident electron reduced by the 
binding energy of that shell.  The ionized atom, with a vacancy in one of its 
shells, will fill the position with an electron in a higher shell. As the electron from 
the higher shell drops down to fill the open position, electromagnetic radiation or 
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characteristic x-rays are released. The energy of these x-rays is equal to the 
difference in the binding energies of the involved shells and is therefore emitted 
in discrete energies (Khan, 2010). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Diagram illustrating the characteristic x-ray process (Khan, 2010). 
 
 
Interactions of Photons with Matter 
A neutral atom becomes ionized if it obtains a positive or negative charge. 
There are two types of radiation, directly ionizing and indirectly ionizing. The 
directly ionizing radiation includes charge particles such as electrons, protons, 
and alpha particles. These particles lose their kinetic energy as they travel 
through matter by ionizing or exciting atoms. Indirectly ionizing radiation are 
uncharged particles such as photons and neutrons. These particles produce 
ionizing particles through the photoelectric effect, Compton effect, or pair 
production (Khan, 2010).  
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 There are three possible results as a photon travels through matter. The 
photon can be absorbed in one or more interactions, scattered in one or more 
interactions, or pass through the matter without any interaction. For 
monoenergetic photons attenuated with good geometry conditions, the equation 
for photon attenuation is: 
 
where Ι is the number of photons that penetrate the matter, Ι0 is the number of 
photons that are present before the matter, x is the thickness of the matter, and µ 
is the linear attenuation coefficient. The linear attenuation coefficient has units of 
cm-1 and is dependent on photon energy, atomic number of the absorbing 
material, and density of the absorbing material. The probability that a photon will 
be absorbed in a thickness of matter is the product of five possible interactions 
giving the total linear attenuation coefficient. The five possible interactions are 
coherent scattering, photoelectric absorption, Compton scattering, pair 
production, and photodisintegration (Hendee & Ritenour, 2002). 
 Coherent scattering is also known as classical scattering or Rayleigh 
scattering. During this process, the incoming photon is scattered at a small angle 
and no energy is transferred to the absorbing material. The incoming photon 
causes an electron in the absorbing material to oscillate. The electron then 
releases that energy at the same frequency as the incoming photon. The 
scattered photon and the incoming photon have equal wavelengths. This process 
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occurs with low photon energies and is of little concern in radiation therapy. The 
diagram in figure 2.4 shows the coherent scattering process. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Coherent scattering process (Khan, 2010). 
 The photoelectric effect involves complete absorption of the incoming 
photon by an atom. The atom transfers the energy to an electron in the K, L, M, 
or N shell. The electron is then ejected from the atom with energy equal to the 
incoming photon minus the binding energy of that shell. The ejected electron or 
photoelectron is often emitted at a 90-degree angle relative to the absorbed 
photon for low-energy photons. As the photon energy increases, the 
photoelectron is ejected in a more forward direction. The vacancy of the ejected 
electron is filled with a higher shell electron that results in the release of 
characteristic x-rays. Monoenergetic Auger electrons can also be emitted if the 
atom absorbs the characteristic x-rays. The photoelectric effect decreases in 
probability with the increase in photon energy (1/E3). The probability increases 
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with the atomic number of the absorbing material (Z3). Figure 2.5 illustrates the 
photoelectric effect. 
 
 
 
 
 
 
 
 
 
Figure 2.5 The photoelectric effect (Khan, 2010). 
 
 The Compton effect becomes the interaction of choice as the photon 
energy increases beyond the K shell binding energy of the absorbing atom. 
During this interaction, the photon collides with an outer shell electron that has a 
binding energy much less than the photon. The photon gives a portion of its 
energy to the electron that is then ejected at an angle φ. The photon is scattered 
at an angle θ with reduced energy. The angle that the two particles travel after 
the collision is determined by the amount of energy given to the electron during 
the collision. The energy of the scattered photon can be calculated from the 
equation below: 
 
where hν0 is the energy of the incident photon (MeV), hνʼ is the energy of the 
scattered photon (MeV), and α is equal to hν0 /0.511 MeV. The Compton effect is 
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independent of atomic number and decreases with increasing energy. The 
illustration in figure 2.6 demonstrates the Compton effect. 
 
Figure 2.6 The Compton effect (Khan, 2010). 
 
 Pair production is a photon interaction with the nucleus of an atom and 
requires energy greater than 1.02 MeV. During this process, all of the photonʼs 
energy is given up to create a negative and positive electron pair. Each particle 
has a rest mass energy of 0.51 MeV. If the incoming photon has energy greater 
than the threshold energy needed to convert the energy into mass, the excess 
energy is shared between the two particles in the form of kinetic energy. A 
diagram of the pair production process is shown in figure 2.7. 
 
Figure 2.7 The pair production process (Khan, 2010). 
 
 
 Photodisintegration also requires that the photon have enough energy to 
overcome the threshold energy needed for the interaction to occur. The threshold 
energy for photodisintegration is much higher because it must overcome the 
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binding energy of a nucleon. As the photon, with very high energy, is absorbed 
by the nucleus of the atom, the atom emits one or more nucleons. In most cases, 
the atom emits a neutron because it does not have to overcome the coulomb 
potential barrier of a proton. Linear accelerators with energies greater than 10 
MeV are capable of this interaction (Cember & Johnson, 2009; Hendee & 
Ritenour, 2002; Khan, 2010). 
Radiation Absorbed Dose 
 The early days of radiology and radiation therapy had no biologically 
meaningful unit for measuring radiation exposure. One form of radiation 
protection was a paper clip attached to a small piece of dental film. A daily 
exposure large enough to detect a shadow of the paper clip on the film, known as 
a “paper clip” unit, was considered the daily maximum dose. For radiation 
therapy, the “skin erythema unit” determined the maximum allowed dose. As 
megavoltage beams with skin-sparing properties became more popular, the need 
for a better measurement of exposure was necessary.  
The international Commission on Radiation Units and Measurements 
(ICRU) accepted the roentgen (R) as the unit for measuring radiation exposure of 
x-rays and gamma-radiation in 1928. The roentgen was originally defined as: 
1R = 1 electrostatic unit (esu) / cm3 air at STP 
Standard temperature and pressure (STP) is defined at 0° C and 760 mm Hg. 
The SI unit for exposure (X) is the number of x-rays or gamma radiation that 
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produces ions, in air, carrying one coulomb of charge, of either sign, per kilogram 
of air. 
X = 1C / kg air 
When 1 electrostatic unit is expressed in Coulombs (1esu = 3.333 x 10-10 C) and 
the volume of air is changed to mass (1 cm3 of air at STP = 1.293 x 10-6 kg), the 
roentgen can be shown to equal: 
1R = 2.58 x 10-4 C / kg air 
Because the definition of exposure requires the ionic charge of either sign to be 
counted, the electrons produced by the photons in the defined volume must 
exhaust all of their energy in that volume of air. Some of the electrons deposit 
their energy outside the volume and will not be measured. Electrons that are 
created outside the volume but measured inside the volume maintain the 
electronic equilibrium. As the photon energy is increased, the range of the 
electrons in air also increases. This makes it difficult to maintain electronic 
equilibrium and limits the definition of exposure to energies below 3 MeV.  
 The measurement of the biological effects caused by ionizing radiation is 
known as absorbed dose. Absorbed dose is expressed as absorbed energy per 
unit mass of tissue. Unlike the definition of exposure, absorbed dose is valid for 
all types of ionizing radiation, including charged particles, all materials, and all 
energies. The SI unit for radiation-absorbed dose is the gray (Gy) and is defined 
as an absorbed radiation dose of one joule (J) per kilogram (1Gy = 1 J/kg). An 
older unit of radiation-absorbed dose, that can still be seen today, is the rad 
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(Radiation Absorbed Dose). One rad is defined as an absorbed radiation dose of 
100 ergs/g (Attix, 1986; Cember & Johnson, 2009; Khan, 2010). The relationship 
between the rad and the gray is: 
1 J = 107 ergs 
1 kg = 1000g 
 
1 Gy = 100 rad 
Biological Effects of Radiation Therapy 
 The science of radiobiology was introduced just one month after W.C. 
Roentgen announced his discovery of x-rays. Radiobiology is the study of the 
biological effects of ionizing and non-ionizing radiation. The objective of radiation 
therapy is to destroy all of the cancer cells without exceeding the tolerance of the 
normal cells. Early radiation treatments were restricted by the low outputs of the 
x-ray machines. There were also strong debates over treatment times and 
fractionation. In 1906, Bergonié and Tribondeau observed that radiosensitivity 
was a function of the metabolic state of the tissue.  Their findings became known 
as the Law of Bergonié and Tribondeau. The law states that stem cells are more 
radiosensitive than mature cell, younger tissues and organs are more 
radiosensitive, cells with a high level of metabolic activity are more radiosensitive, 
and faster proliferating cells are more radiosensitive.  
 The biological response to radiation is also determined by a number of 
physical factors. The linear energy transfer (LET) is a measure of the quality of 
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the radiation and is defined as the rate at which energy is transferred by the 
ionizing radiation to the irradiated medium. As the LET increases, the biological 
response increases. The LET for high energy x-rays is approximately 0.2 keV/µm 
and 50.0 keV/µm for fast neutrons. The relative biologic effectiveness (RBE) 
quantitatively describes the biological damage relative to the LET. The RBE is 
defined as the dose of standard radiation necessary to produce a given effect 
divided by the dose of test radiation necessary to produce the same effect.  The 
standard radiation used for the definition of RBE is 200 to 250 kVp x-rays. The 
period of time that the radiation is delivered also determines the response to 
radiation treatments. A dose that is delivered continuously at a low dose rate is 
protracted. A protracted dose is less effective because of the long exposure 
times and low dose rate. A total dose that is given in equal parts separated by a 
period of time is known as fractionation and has an important role in radiation 
therapy.  
 Deoxyribonucleic acid (DNA) is the most critical target in the cell and 
damage to the DNA is the main cause of a biological effect. The cell also 
contains less critical targets that, when damaged, can cause cell death. 
Absorbed ionizing radiation can damage the cell by direct or indirect action. In the 
direct action, the initial ionizing event occurs on the target of the cell. This leads 
to a physical or chemical event that results in damage to the cell. The ionizing 
radiation of an indirect action interacts with noncritical molecules, such as water, 
to cause damage to the cell. Because the cell is composed of 80% water, 
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irradiation of water is the main interaction in the body. When water is irradiated, 
short lived free radicals (H• and OH•) are produced. These free radicals can also 
join to form hydrogen peroxide (H2O2) and hydroperoxyl (HO2•), which are 
considered to be the main damaging products of water irradiation due to their 
toxic effects on the cell (Khan, 2007). 
 Fractionation and the 4Rʼs of radiotherapy (repair, reoxygenation, 
repopulation, and redistribution) exploit the small differences between the 
radiosensitivity of tumor cells and normal cells. Sublethal damage to certain 
normal cells exposed to radiation show a greater chance of making repairs than 
do tumor cells. To allow enough time for normal tissue to repair, there should be 
a minimum interval of six hours between treatments. Oxygen is a radiation 
sensitizer that is often not well supplied to the center of tumors. These hypoxic 
cells require approximately three times the dose of an oxygenated cell to kill and 
can be reoxygenated in a fractionated treatment course. Cancer cells usually 
divide faster than normal tissue cells and this repopulation of tumor cells 
continues or accelerates during a course of treatment. The course of treatment 
should not be overly protracted or the dose required to control the tumor might 
exceed the normal tissue tolerances. Cells irradiated in the mitotic phase of the 
cell cycle are the most sensitive and cells in the late synthesis stage are the most 
resistant to radiation. Cell surviving a single dose tend to be partially 
synchronized. This will leave more cells in the late synthesis stage and where 
this bolus of cells appears in the cell cycle during the next fraction of radiation 
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could be a benefit or a disadvantage. There has been no evidence that the 
advantage of redistribution can be achieved in a clinical setting (Bushong, 2008; 
Fritz-Niggli, 1995; Khan, 2007). 
Diodes 
 Solid detector media offer a great advantage over the gas-filled detectors 
because their solid densities are 1000 times greater than that for gas. This allows 
the solid detector size to be much smaller. One type of solid detector, the 
scintillation counter, is limited by poor energy resolution. This detector requires 
many inefficient steps in order to generate an electric signal and, as a result, 
requires around 100 eV to produce one information carrier. The energy resolution 
can be improved with the use of semiconductors. Semiconductors became 
available in the 1960s and provide the largest number of carriers for a given 
radiation event than any other common detector type. The modern versions of 
these detectors are referred to as semiconductor diode detectors or solid-state 
detectors. Not only do they offer superior energy resolution and small detector 
size, they are also desired for their relatively fast timing characteristics, an 
effective thickness that can be matched to a preferred application, higher 
sensitivity, and ruggedness.  
 The electrons of a crystalline material are confined to either the valence 
band or the conduction band. The valence band is filled with outer-shell electrons 
that are bound to specific lattice sites by covalent bonds. The conduction band is 
made up of electrons that are free to migrate through the crystal and contribute to 
 
21 
the electrical conductivity of the material. The two bands are separated by a 
bandgap. The size of the bandgap determines if the material is a semiconductor 
or an insulator. If number of electrons in the material completely fills the available 
electron sites in the valence band and leaves the conduction band empty, the 
material would show no electrical conductivity. The energy required for an 
electron to cross the bandgap for an insulator is 5 eV or more and the 
semiconductor requires less than 1 eV. 
 When an electron in the valence band becomes excited and has enough 
energy to cross the bandgap, a hole is created in the valence band. The hole 
represents a positive charge. The electron is now in the conduction band and can 
be made to move under the influence of an applied electric field. The hole will 
move in the opposite direction of the electron. The electron-hole pair is the similar 
to the ion pair for gases.  
 Silicon crystal diodes used for dosimetry are doped with impurities to 
make n-type semiconductors or p-type semiconductors. When the silicon is 
mixed with elements from group V of the periodic table, it becomes an electron 
donor or n-type semiconductor. If the silicon is mixed with elements from group 
III, it becomes an electron receptor or p-type semiconductor.  
 A p-n junction diode contains a section of p-type material and a section of 
n-type material. The p-area contains has an excess holes and the n-area has an 
excess of electrons. As electrons from the n-region and holes from the p-region 
cross sides to establish equilibrium, a depleted zone is created. This depleted 
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zone develops an electric field that resists further movement of charge carriers 
after equilibrium is established. Electron-hole pairs are created in the depleted 
zone when the diode is irradiated. The electric field of the depleted zone carries 
the electrons and holes out of the zone causing a radiation-induced current. 
Figure 2.8 shows a diagram of a silicon p-n diode. 
 
 
 
Figure 2.8 Diagram of silicon p-n diode (Khan, 2010). 
The energy required to produce an electron hole pair in silicon is 3.5 eV. 
The is much less than the 34 eV necessary to create an ion pair in a gas-filled 
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detector and produces 10 times the charge carriers that the gas-filled detector 
would produce. Diodes do have some limitations as dosimeters. Diodes show 
energy dependence in photon beams of nonuniform quality. Diodes also exhibit 
angular dependence and should be evaluated with a detector that is known to 
have no angular dependence. Temperature changes may show a small change 
in the diode reading. The diode is independent of humidity and pressure. Very 
large doses of ionizing radiation can permanently damage a diode and the diode 
should be checked routinely for stability and accuracy of calibration (Diefenderfer 
& Holton, 1994; Khan, 2010; Knoll, 2000). 
The Linear Accelerator 
 Electron linear accelerators have been used in the clinics to produce fast 
electron beams or generate x-rays for radiation therapy treatments since the 
1950ʼs. Clinical linear accelerators are able to produce radiation beams that are 
variable and well defined in size. The beam pattern is able to be precisely 
controlled in a uniform or non-uniform dose pattern and remain stable over the 
period of the treatments. This beam is maneuver so it can be applied to multiple 
positions directed at the patient. The delivered radiation dose is accurately 
monitored and a high standard of electrical, mechanical, and radiation safety 
interlocks are applied. 
 The linear accelerator or linac is a waveguide structure energized by 
short-pulsed microwave frequencies in the range of 3000 MHz. The microwaves 
are generated by a magnetron or a klystron. The magnetron functions as a high-
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powered oscillator that generates microwave pulses. The cylindrical shape of the 
magnetron contains a centrally located cathode and an outer anode. The anode 
contains a symmetrical array of resonant cavities arranged around a cylindrical 
hole. The cathode generates electrons by thermionic emission with an inner 
filament. The whole structure is placed in a magnetic field to steer the electrons 
emitted from cathode away from the anode. The resonant cavities of the anode 
oscillate with potential differences. As electrons cross the mouth of these 
cavities, they either accelerate or decelerate. This action causes the electrons to 
bunch and move in complex spirals while radiating energy in the form of 
microwaves. Magnetrons with a 2 MW peak power output are used to power 
linacs with energies of 6 MV or less. The diagram in figure 2.9 shows a cutaway 
view of a magnetron.  
 
 
 
Figure 2.9 Magnetron diagram of anode and cathode (Khan, 2010).  
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 Higher energy linacs use a klystron for their source of microwaves. The 
klystron is a microwave amplifier that is driven by a low-powered microwave 
oscillator. A cathode produces electrons that are accelerated by a negative pulse 
into a cavity known as the buncher cavity. This cavity is energized by a source of 
low-powered microwaves that induce an alternating current across the cavity. A 
process known as velocity modulation occurs as the electric field alters the 
velocity of the electrons. The action of slowing or speeding up the electrons 
cause them to bunch as they travel across a drift tube. A retarding electric field is 
induced as the electrons make there way to a catcher cavity. The electric field 
causes the electrons to decelerate and the kinetic energy is released as 
microwaves. Figure 2.10 shows a cross-section of a klystron. 
 
 
Figure 2.10 Cross-section of a klystron (Khan, 2010). 
 The pulsed microwaves produced by a magnetron or klystron are injected 
into an accelerating tube at the same time electrons from an electron gun are 
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injected. The initial energy of the injected electrons is about 50 keV. The 
accelerating tube or waveguide can accelerate the electrons with either traveling 
or stationary electromagnetic waves. The traveling waveguide requires the 
absorption of the residual power at the end of the guide to prevent a backward 
reflection of the wave. Figure 2.11 shows electrons at points A, B, C, and D of the 
traveling wave in relation to the electric field. The electrons accelerate as they 
gain energy from the sinusoidal electric field. The electron at point A will receive 
a force from the electric field that accelerates it to point A'. The electron at point B 
will receive a stronger force that will move it up in phase to the A position. The 
electron at point D will decelerate and will be overtaken by point A. This causes 
the electrons to bunch on the wave as they increase in velocity.  
 
 
 
 
Figure 2.11 Travelling wave accelerator (Greene & Williams, 1997) 
 The standing waveguide design uses coupling cavities to introduce the 
microwave power. This allows the system to be more efficient as each of the 
cavities can be optimizes. Figure 2.12 shows a diagram of a standing waveguide. 
The cavities numbered 2, 4, and 6 are the nodes of the system and particles 
passing in these cavities receive no energy. These cavities are removed to the 
side as seen in part (c). Cavities 1, 3, and 5 are the antinodes and the arrows 
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show the direction of the force on a charged particle. When the time for a particle 
to travel from 1 to 3 equals one half of a cycle, the reflected wave allows the 
particle to be accelerated in the same direction for both cavities.  
 
 
Figure 2.12 Standing waveguide (Greene & Williams, 1997). 
 The electrons exit the waveguide in the form of a high-energy pencil beam 
of about 3mm in diameter. The electrons travel through a beam transport system 
that consists of bending magnets, focusing coils, and other components. The 
length of the waveguide for high-energy electrons may require the electrons to be 
bent at an angle of 90 or 270 degrees before striking the target.  Most linacs are 
capable of producing electron and x-ray beams. For electron beams, the pencil 
beam of electrons strikes a scattering foil to spread the electrons into a nearly 
monoenergetic uniform fluence. The scattering foil is thin enough to avoid 
creating large amounts of bremsstrahlung photons. A water-cooled tungsten 
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target takes the place of the scattering foil when x-rays are produced. The 
bremsstrahlung interaction produces an average energy of about one third of the 
maximum electron energy that strikes the target. The photon beam travels 
through a flattening filter placed just after the target and the fixed primary 
collimator.  
 
 
Figure 2.13 Treatment head components (Khan, 2010). 
The flattening filter is used to reduce the forward intensity of the 
megavoltage beam and make the beam uniform across the field.  Dose 
monitoring chambers are placed after the flattening filter or scattering foil. The 
dose rate, integrated dose, and field symmetry are all monitored with these 
sealed ion chambers. A set of movable collimator jaws and multileaf collimators 
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(MLC) follow the dose monitoring chambers. These beam-collimating devices 
allow for treatment field sizes from 0 x 0 to 40 x 40 cm2 at 100 cm from the target. 
The source of radiation is allowed to rotate about a horizontal axis by turning the 
gantry. The axis of rotation for the gantry and collimator system is known as the 
isocenter. The isocenter on modern linacs is 100 cm from the target. Figure 2.13 
shows the components of the treatment head for an x-ray (a), an electron setup 
(b) and a gantry diagram (c) (Greene & Williams, 1997; Khan, 2010). 
Intensity-Modulated Radiation Therapy 
 Once the decision is made by a radiation oncologist and the patient to use 
radiotherapy as a course of treatment, the process of creating a blueprint for the 
treatments begins. The treatment planning process involves determining a 
number of parameters that will optimize managing the patientʼs cancer. The 
parameters include target volume, dose-limiting structures, treatment volume, 
dose prescription, treatment machine settings, and adjuvant therapies.   
 The first step is to localize the target. Imaging modalities such as 
computed tomography (CT), magnetic resonance imaging (MRI), ultrasound, and 
positron emission tomography (PET) can be used to locate the target and critical 
dose-limiting structures. A CT simulator is used to image the treatment region, 
slice by slice, with the patient in a position that is reproducible on the treatment 
table. Other imaging modalities can be used to visualize the anatomy by fusing or 
registering the images to the CT.  A CT simulator is similar to a conventional CT. 
The main differences are in the tabletop and the gantry size. A flat tabletop, 
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identical to the one for the linac, is used to insure that the positioning surface is 
the same and reproducible. The gantry of a CT simulator is larger, known as a 
large bore, to allow more space for patient positioning.  CT uses x-rays that are 
rotated around the patient, in a plane, to acquire multiple projection views. The 
projections are reconstructed with algorithms to generate an image matrix. Each 
pixel in the matrix gives an accurate measurement of the linear attenuation 
coefficients (µ) relative to water in terms of CT units or Hounsfield units (HU). The 
relationship between the CT unit and the linear attenuation coefficient is given as: 
 
where µw is the linear coefficient of water. The 3-D images provided by the CT of 
the patient, in the treatment position, are transferred to a treatment planning 
system where the images are used of contouring patient anatomy and treatment 
planning.  
 
Figure 2.14 Contouring anatomical structures on CT image (Khan, 2010). 
Contouring the patientʼs anatomy from the CT data set is an important and 
time-consuming process in the treatment planning stage. The target volumes and 
critical structures must be outlined for each of the CT slices that will be used in 
the treatment field. The contours will be used to define the shape of the radiation 
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beams. Margins are also added to these volumes for treatment uncertainties. An 
example of contouring the optic nerves, eyes and lens of the eye on a CT slice is 
shown in figure 2.14. The International Commission on Radiation Units (ICRU) 
recommends a system of delineating contouring volumes and margins in ICRU 
Report 50 and Report 62. The gross tumor volume (GTV) is the contour of any 
tumor, metastatic lymphadenophathy, or metastases that is visible, palpable, or 
seen by imaging. The clinical target volume (CTV) includes the GTV and any 
additional tissue that may include tumor cells. The internal margin (IM) is a 
margin on the CTV that compensates for motion of the CTV from internal 
physiological motion. The internal target volume (ITV) is the combination of the 
CTV and the IM. For errors in patient setup and to account for patient movement 
during treatment, a setup margin (SM) is added. The planning target volume 
(PTV) is the combination of the CTV, IM, and the SM. The margins that are 
added for the IM and SM may vary in size around the CTV. All of the above terms 
are used to define tissue that requires an adequate dose to manage the cancer. 
The ICRU also recommends using a system to delineate uninvolved tissue that is 
critical to the success of the treatment. An organ at risk (OAR) is defined as an 
organ that could compromise the outcome of the treatment if damaged by the 
radiation. A margin is added to the OAR to include organ motion and setup error. 
The planning organ at risk volume (PRV) is the OAR and the additional margin. 
An effort is made to reduce the dose to this structure. Figure 2.15 is a diagram 
showing the volumes and margins recommended by the ICRU.  
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Figure 2.15 ICRU recommendations for volumes and margins (Khan, 2010). 
 
 Once the contouring is completed, the focus turns to developing a 
treatment plan to meet the goals of the treatment. A decision is made by the 
radiation oncologist to construct a three-dimensional conformal treatment plan (3-
D CRT) or an intensity-modulated radiation therapy treatment plan (IMRT). 3-D 
CRT uses 3-D anatomical information to conform the dose distribution close to 
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the target and minimize the dose to the normal tissue. The treatment planner 
selects the direction of the radiation beams and designs the beam apertures for a 
3-D CRT.  Multiple beams are used in the treatment, selected from coplanar or 
noncoplanar angles with respect to the transverse plane of the patient, to include 
the PTV while avoiding the normal tissue as much as possible. The collimators, 
custom blocks, or multileaf collimators (MLC) are use to design the beam 
aperture. MLCs are tungsten alloy blocks with a width of 1 cm or less. A typical 
MLC system has 80 to 120 pairs of these leaves that allow less than 2% 
transmission of the primary beam.  
Figure 2.16 Profile of a uniform 20 cm x 20 cm 6MV photon beam at 10 cm 
depth. 
 
 Traditional radiation therapy and 3-D CRT use beams with a uniform 
intensity profile. The uniformity of the beam is specified by flatness and 
symmetry. Flatness is defined as the variation of dose relative to the central axis 
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over the central 80% of the field size at 10 cm depth. An acceptable tolerance for 
flatness is ±3%. Symmetry is defined as the dose at any pair of points situated 
symmetrically with respect to the central axis. The two points should not differ by 
more than 2%. Figure 2.16 shows a uniform profile of a 20 cm x 20 cm 6MV 
beam at 10 cm depth. 
 The main difference between IMRT and 3-D CRT is that IMRT uses 
intensity modulation to conform the dose to the target. Intensity modulation for 
IMRT beams is accomplished by the MLCs. An example of an intensity-
modulated beam is shown in figure 2.17.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17 Profile of an intensity-modulated beam (Khan, 2010). 
 
The treatment-planning computer computes the intensity modulated beam 
profiles by first assuming uniform dose inside the tumor volume. The density of 
the patient is known from the CT. Fourier-back projection methods are used to 
compute the beam profiles that must enter the patient to give the uniform dose in 
the tumor volume.  The computed profiles contain negative dose values that are 
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not possible. This problem is resolved by algorithms that will search for a profile 
that best fits the required dose. The process is called inverse treatment planning 
because it begins with the desired dose and works backwards to obtain the 
delivered beam intensity.  
 The planner still often chooses the beam arrangements used for the IMRT 
plan. Although there are some vendors that offer beam direction optimizers, the 
required computer speed and memory is costly and currently shows little 
advantage in the plan outcomes.  After the number of beams and directions are 
selected, the next step is to assign values to the parameters that will drive the 
optimization algorithms. The first value is the dose objective. The planner enters 
the desired dose to the contoured structures. This is a maximum and/or a 
minimum dose. A PTV, for example, would have a value for the maximum dose 
of 0% of the PTV receives a dose that is slightly higher than that prescribed by 
the radiation oncologist. This is used to control the algorithm from accepting large 
areas of unacceptable high dose. The minimum dose for the PTV would be 100% 
receives the prescribed dose. The minimum dose is only applied to target 
structures. OAR may have one or more maximum doses. This allows the planner 
to step down the dose that is given to the structure. For example, it is not 
physically possible to avoid the entire rectum in a prostate treatment. The 
maximum dose may be entered as 10% can receive 4500 cGy, 30% can receive 
3000 cGy, and 50% can receive 2000 cGy. This permits the algorithm to add 
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higher doses to a small portion of the rectum in order to get the required dose to 
the PTV. 
 The next parameter is the weight or priority. This value ranges from 0-100 
or 0-1000 depending on the system. It is a way of telling the algorithm which 
structure is more important if it is impossible to deliver the target dose and 
maintain an organ tolerance dose at the same time.  
 After the parameters are set, the optimization algorithm is started. The 
process goes through several iterations to minimize the value of a cost function. 
An example of a cost function that is used is: 
 
 
where Cn is the cost of the nth iteration. D0 is the desired dose at some point (r) in 
the patient. Dn is the computed dose at the same point. W is the weight factor or 
priority and N is the number of dose points.  
 Once the fluence distribution for the beams is calculated, the MLCs are 
used to deliver the intensity-modulated output of the linac. The MLCs can deliver 
the fluence in a “step and shoot” method or a dynamic delivery. The “step and 
shoot” method takes the modulated fluence of a beam and breaks it up into 
subfields of uniform beams. The beam is terminated as the MLCs move from one 
subfield to the next. The disadvantage of this method is that some of the 
subfields contain a low number of monitor units (MU) and some linacs can be 
unstable in this range. A MU is defined as 1 rad at a reference depth for a field 
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size of 10 x 10 cm2 and a known source to calibration distance. The dynamic 
deliver or “sliding window” technique does not terminate the beam as it delivers 
the modulated intensity. The MLC leaf pairs are moving simultaneously in a 
unidirectional motion with each leaf having a different velocity as a function of 
time. The MLC leafs are capable of moving at a speed of 2 cm per second.  
 Because each field in an IMRT treatment consist of several beamlets with 
individual intensities, a verification calculation is difficult to accomplish by hand. A 
number of techniques, instruments, and software are available to verify an IMRT 
plan and some form of verification should be completed before the patientʼs first 
treatment. The form of verification that is most often used involves a verification 
plan that is calculated on a rectangular phantom. The treatment planning system 
uses the same beam parameters (MUs and MLC patterns) and places them on a 
phantom. A dose distribution at a reference depth is calculated and used to 
compare with a measured dose distribution from film or a diode array at the same 
reference depth. The patient and phantom dose will be different due to 
attenuation and shape. This is accepted by assuming that the dose measured on 
the phantom has the same order of accuracy as a dose measured on a patient 
(Hendee & Ritenour, 2002; Khan, 2007; Khan, 2010). 
Lung Cancer Treatments 
 The lungs extend from the diaphragm to about 1.5 to 2.5 cm superior to 
the clavicle and are protected by the rib cage. The superior portion of the lung is 
known as the apex and the inferior portion is termed the base. The heart and 
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other structures in the mediastinum separate the pair of lungs. Each lung is 
enclosed in a protective layer called the pleural membrane and is divided into 
lobes by fissures. The right lung has three lobes and the left lung has two. The 
principle function of the lung is to supply the cells of the body with oxygen and 
remove the carbon dioxide produced by cellular activities. This process is known 
as respiration. The exchange of respiratory gases between the lungs and the 
blood takes place in the alveolar and capillary walls by diffusion. A respiration 
cycle includes one inspiration and one expiration. A healthy adult, at rest, 
averages about 12 respirations in a minute. For inspiration to occur, the pressure 
inside the lung needs to become lower than the pressure in the atmosphere 
(about 760 mmHg). This is accomplished by increasing the volume of the lungs. 
The contraction of the diaphragm, external intercostals, and other muscles cause 
the lung volume to increase. The process is reversed with expiration. During 
expiration, the pressure in the lung is greater than the atmosphere. The volume 
of lung is reduced when those same muscles responsible for inspiration relax. 
Respiration is an involuntary action with some limited control of the frequency, 
magnitude of displacement, and breath-holds by the individual.  
 Lung cancer is the leading cause of cancer-related deaths in both men 
and women. Of the patients with lung cancer, it is estimated that greater than 
50% will require at least one course of radiation therapy (RT) and 45% will 
receive RT as part of their initial treatment. The treatment of lung cancer is based 
on the stage of the tumor, the medical condition of the patient, and the type of 
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lung cancer. The tumor-node-metastasis (TNM) staging system is used to 
classify lung cancer. T0-T4 describes the extent of the primary tumor. N0-N3 
classifies the secondary or lymphatic involvement. M0 or M+ depict the presents 
of distance metastasis. The two types of lung cancers are non-small cell lung 
cancer (NSCLC) and small cell lung cancer (SCLC). 
 The treatment for NSCLC depends on the stage and the ability to remove 
the tumor with surgery. The highest cure rates are from lobectomy or 
pneumonectomy cases. Because of age or other medical conditions, only about 
20% of patients with NSCLC are eligible for definitive or curable surgery. RT can 
be used in NSCLC as a definitive treatment for early stage cancer. RT can also 
be used in combination with chemotherapy for patients with nodal involvement. 
Neoadjuvant radiation is a preoperative course of RT that has been shown to 
improve survival rates for early stage NSCLC.  
 Only about 15% to 20% of lung cancer cases are SCLC. Chemotherapy is 
the main modality of treatment because of the probability of early metastasis.  RT 
is considered in patients that have disease confined to the chest, no pleural 
infusion and the disease can by included into one RT field. Prophylactic brain 
irradiation is often included in patients with SCLC to reduce the incidence of brain 
metastasis.  
 A RT dose of greater than 70 Gy is often given to a tumor when the 
amount of normal tissue is small. If the tumor is large and the amount of normal 
tissue included in the fields is large, a lower dose of 66 Gy may be prescribed. 
 
40 
The critical structures in the treatment of lung cancer include the lung, 
esophagus, spinal cord, and heart. Emami et al. presented a summary of 
tolerance doses in a National Cancer Institute sponsored study. For lung 
tolerance doses, a 5% chance of developing pneumonitis in 5 years from 
irradiation of one-third of the lung was 45 Gy, for two-thirds was 30 Gy, and the 
whole lung was 17.5 Gy. Doses that may result in a stricture or perforation to the 
esophagus are 60 Gy (one-third), 58 Gy (two-thirds), and 55 Gy (whole). A 
chance of pericarditis may develop with dose exceeding 60 Gy (one-third), 45 Gy 
(two-thirds), and 40 Gy (whole) to the heart. The spinal cord is limited to 50 Gy 
maximum dose to any point.  
 Lung IMRT has the ability to reduce the dose to normal structures and 
escalate the dose given to the tumor. Liu et al. found IMRT reduced the 
percentage of lung that received a dose greater than 20 Gy and the mean lung 
dose lowered by a median of 8%. Grills et al. showed that IMRT of the lung 
allows for an increase in dose of 125% to 130% compared with dose given by 3-
D CRT.  
 To deliver IMRT to a lung tumor, it is critical to accurately define the IM to 
insure tumor coverage and dose sparing. The lung tumor motion can be 
substantial and heterogeneous. Mageras et al. studied the tumor motion, caused 
by respiration, for 12 lung cancer patients. The results showed a GTV 
displacement of greater than 1 cm in the superior-inferior direction for 7 of the 
patients. Two patients showed an anterior-posterior GTV displacement of greater 
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than 1 cm.  Seppenwoolde et al. studied 20 patients and found similar results in 
the superior-inferior direction. This study and also one by Shirato et al. found that 
the position of the tumor is most stable and reproducible during the exhale phase 
of the breathing cycle.  
 The American Association of Physicist in Medicine (AAPM) Task Group 76 
provides a clinical process guide for managing respiratory motion. A review of the 
respiratory motion literature by the task group concluded that no general pattern 
of motion behavior could be assumed for a particular patient. The report 
recommends the use of respiratory management techniques if the tumor range of 
motion is greater than 5 mm in any direction or significant normal tissue sparing 
can be obtained. The report also recommends that the entire range of motion be 
included in the IM if a respiratory management device is not used. In cases 
where a management device is used, only the motion expected during the 
radiation treatment should be considered for the IM (American Cancer Society, 
2009; Emami et al., 1991; Grills et al., 2003; Keall et al., 2006; Khan, 2007; 
Khan, 2010; Liu et al., 2004; Machtay et al., 2005; Mageras et al., 2004; 
Seppenwoolde et al., 2002; Shirato, Seppenwoolde, Kitamura, Onimura, & 
Shimizu, 2002).    
4D-CT 
 Advancements in imaging and techniques have provided several methods 
that can be used in the clinic to accurately determine a tumors position and range 
of motion during a respiratory cycle. These methods include direct visualization 
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under fluoroscopy, multisets of slow CT images, multiphases of CT images with 
breath-hold technique, and 4-D CT. 
 Conventional fluoroscopy can be used to visualize the tumor motion in 
each dimension. The maximum range of the motion can be used to customize 
the IM for the treatment plan. This simple method has some limits to the accuracy 
of the margin. Lung tumors can be difficult to visualize with fluoroscopy and the 
shape change of the tumor cannot be measured clearly. The measured IM is 
added to the GTV contour of the treatment planning CT to create the PTV. An 
issue of concern is that the CT images could have been taken from any phase in 
the breathing cycle. If the GTV was imaged on the CT at a phase where the 
motion was in the most superior position, then the added margin will not fully 
cover the inferior part of the target and treat unnecessary normal tissue 
superiorly.  
 During the slow CT scanning method, the CT scanner is operated very 
slowly. The scanner takes multiple images for each slice position. The time the 
scanner remains in each position extends over several respiratory phases. An 
average of the multiple scans are used to show the full extent of the tumor 
motion. Because only one CT is obtained, the process is equal in complexity to a 
free-breathing CT and is available on most CT scanners. The disadvantages of 
the slow CT method are the increased dose compared to the free-breathing CT 
and the loss of resolution due to motion blurring. 
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 A solution to the blurred images obtained in the slow CT method is the 
breath-hold technique. This technique uses two separate CT scans. One taken 
after inhalation as the patient holds their breath and one after exhalation as the 
patient hold their breath. The two CT data sets can be fused together to create 
one data set showing the volume of tumor motion. Because patients spend a 
greater amount of time in the exhale position, this CT should be used for the 
dose calculation. A free-breathing CT can also be used to calculate the dose and 
fused with the other data sets. The disadvantages of the breath-hold technique 
are the increased scanning time (greater than two or more scans) and the 
reproducibility of the breath-hold. The patient is often coached on the breath-
holds and deep breaths should be avoided.  
The 4-D CT uses an 8 to 16 multislice CT scanner to acquire images while 
the table is in one position. The CT scanner remains in this position for one or 
more respiratory cycles while acquiring images and then repeats the process at 
the next table position. The respiratory phase of each image is recorded. The 
respiratory phases are determined by monitoring an external respiration signal 
(abdominal motion) or internal fiducial markers. The images are then sorted 
according to the respiratory phase and a 3D data set is reconstructed for each 
phase. The respiratory cycle is often divided into ten phases. Figure 2.18 shows 
the process of acquiring and reconstructing a 4-D CT (Keall et al., 2006; Khan, 
2007; Khan, 2010). 
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Figure 2.18 4-D CT process (Keall et al., 2006). 
Respiratory Gating Treatments 
 Radiation that is delivered within a particular portion of a patientʼs 
breathing cycle is known as respiratory gating and was first studied in Japan in 
the late 1980s and early 1990s. The portion of the breathing cycle that is 
irradiated is referred to as the gate. This technology requires precise real-time 
tumor localization and prompt linac reaction to a gating signal. A gated 
radiotherapy treatment has the potential for margin reduction, target dose 
escalation, and dose reduction to the adjacent normal tissue.  
 Either an external respiratory signal or internal fiducial markers determine 
the real-time detection of the tumor. For the internal fiducial marker technique, 
several options are available. A popular method uses 2 mm-diameter gold 
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spheres that are implanted in or near the tumor. These markers are then tracked 
in all three dimensions by a pair of stereotactic kilovoltage x-ray imaging 
systems.  The radiation is delivered when the markers are in the desired position. 
The external respiratory signal uses an infrared reflective plastic cube placed on 
the patientʼs abdomen. A tracking camera that is sensitive to visible and infrared 
light records the motion of the cube as the abdomen rises and falls in the 
breathing cycle. The radiation is delivered when the cube is at the desired 
position. 
 Gating can be performed at any stage in the breathing cycle. The most 
common segments are at inhale or exhale portions of the breathing cycle, where 
the tumor motion is at a minimum.  The respiratory signal can be tracked using 
the amplitude or the phase of the signal. The amplitude method triggers the 
treatment when the marker is at a certain position. The phase method triggers 
the radiation to occur when the calculated breathing phase is at a certain angular 
phase. The duty cycle is the ratio of beam-on time and treatment time. As the 
duty cycle decreases, the range of tumor motion decreases and the treatment 
time increases (Jiang, 2006; Keall et al., 2006; Vedam, Keall, Kini, & Mohan, 
2001). Figure 2.19 shows diagrams of amplitude gating and phase gating 
treatments using Varianʼs Real-Time Position Management (RPM) system. The 
left side of each diagram shows the phase dial. This tracks one complete 
breathing cycle. The left side of the dial is the inspiration and the right side is the 
expiration phase. When treated with phase gating (b), the arrows can be adjusted 
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to the selected phases. The right side of each diagram shows the motion signal 
displayed as a respiratory waveform. The horizontal lines in (a) are the amplitude 
gating thresholds and are only shown during amplitude based gating. The beam 
enable signal is the square waveform shown in each diagram. 
 
Figure 2.19 Diagram showing (a) amplitude gating and (b) phase gating (Vedam 
et al., 2001). 
 
As the magnitude of this motion increases, the amount of residual motion 
remaining in the gating interval also increases. With the fixed gating window of 
30%-70% used in this study, the amount of residual motion is equal to 40% of the 
tumor motion. The 50% phase represents the point of full expiration where the 
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tumor has on motion. Between the 50% and 100% phases, inspiration is 
occurring and the full range on the tumor motion is seen. By limiting the beam on 
time for this period to the 50% to 70% phases, only 20% of this motion is seen. 
As the breathing cycle reaches full inspiration at the 100% phase, expiration 
begins and the full range of the tumor motion appears again as the tumor travels 
between the 0% and 50% phases to return to its origin. By limiting the beam on 
time for this portion of the breathing cycle to the 30% to 50% phases, another 
20% of the tumor motion is seen. 
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3. Materials and Methods 
Treatment Planning Process 
 Four lung IMRT plans were selected for this study to represent a range of 
treatment field sizes. Each plan, labeled small, medium, large, and split field, had 
been approved for past patient treatments. Because of the design limitations of 
the MLC, field sizes larger than approximately 15 cm are split into subfields. This 
inherent limitation is represented in the split field size plan. Each of the plans 
included a 4D-CT data set that was acquired during simulation. The 4D-CT 
images were obtained with a GE Discovery PET/CT scanner equipped with 
Varianʼs Real Time Position Management (RPM) system. The RPM system uses 
a plastic block with two retroreflective markers placed with a vertical separation of 
3 cm to sense the respiratory motion. The marker was placed on the abdomen of 
each patient during the CT scan. The camera is equipped with an illuminator ring 
that emits infrared light. The infrared light reflects back to the camera from the 
passive markers on the block. This allows the movement of the marker block to 
be tracked with the RPMʼs tracking camera. The position of the marker block 
versus time is then relayed to the CT scanner to create the 4D-CT. The images 
of the CT were exported to a GE Advantage Workstation with 4D visualization 
software. Here the images are reconstructed into 10 phases of the breathing 
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cycle with 0% being full inspiration, 50% being full expiration, and 100% being full 
inspiration. The CT data sets that represented the 30% to 70% phases of the 
breathing cycle were averaged and exported to the treatment-planning computer 
to be used for treatment planning. 
 The Varian Eclipse treatment planning system was used to create the 
IMRT plans investigated in this study. The planning process began with the 
dosimetrist and the radiation oncologist contouring the tumor volume and critical 
structures. The radiation oncologist then determined a prescription for the tumor 
dose and constraints for the normal tissue structures. These values were then 
used to create the optimization parameters for the IMRT algorithm. The plans 
were reviewed by the radiation oncologist and approved for treatment. Tables 
3.1thru 3.4 show the beam settings use for each of the plans. Figures 3.1 thru 3.4 
show the beam arrangements and isodose lines for the selected plans. Yellow 
lines display the beam projections from the skin surface to the target. The 
isodose lines are the several colors that conform around the target. Each 
represents a percentage of the prescribed dose. Other colored lines represent 
the contours of structures such as spinal cord, lung, and heart. 
Table 3.1 Small field size plan beam parameters. 
Small Field Size Plan Beam Parameters 
Field 
ID Energy MLC 
Gantry 
Angle 
(deg) 
Collimator 
Angle 
(deg) 
Couch 
Rotation 
(deg) 
Field 
X 
(cm) 
X1 
(cm) 
X2 
(cm) 
Field 
Y 
(cm) 
Y1 
(cm) 
Y2 
(cm) 
SSD 
(cm) MU 
01 
255 6MV Dynamic 255 0 0 4.3 2.3 2.0 2.8 1.3 1.5 84.1 81 
02 
285 6MV Dynamic 285 0 0 4.6 2.3 2.3 2.8 1.3 1.5 89.6 70 
03 
320 6MV Dynamic 320 0 0 4.6 2.3 2.3 2.8 1.3 1.5 91.8 71 
04 
0 6MV Dynamic 0 0 0 4.3 2.3 2.0 2.8 1.3 1.5 93.3 65 
05 
35 6MV Dynamic 35 0 0 4.0 2.0 2.0 2.8 1.3 1.5 92.9 69 
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Figure 3.1 Transverse view of small field size plan with beams displayed. 
 
 
Table 3.2 Medium field size plan beam parameters. 
Medium Field Size Plan Beam Parameters 
Field 
ID Energy MLC 
Gantry 
Angle 
(deg) 
Collimator 
Angle 
(deg) 
Couch 
Rotation 
(deg) 
Field 
X 
(cm) 
X1 
(cm) 
X2 
(cm) 
Field 
Y 
(cm) 
Y1 
(cm) 
Y2 
(cm) 
SSD 
(cm) MU 
01 
340 6MV Dynamic 340 0 0 5.6 2.8 2.8 4.0 2.0 2.0 88.2 69 
02 
15 6MV Dynamic 15 0 0 6.6 3.3 3.3 4.0 2.0 2.0 88.0 64 
03 
40 6MV Dynamic 40 0 0 7.0 3.5. 3.5 4.0 2.0 2.0 87.6 65 
04 
70 6MV Dynamic 70 0 0 7.0 3.5 3.5 4.0 2.0 2.0 87.2 68 
05 
110 6MV Dynamic 110 0 0 6.0 3.0 3.0 4.0 2.0 2.0 83.2 73 
06 
140 6MV Dynamic 140 0 0 5.3 2.5 2.8 4.0 2.0 2.0 83.8 72 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Transverse view of medium field size plan with beams displayed. 
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Table 3.3 Large field size plan beam parameters. 
Large Field Size Plan Beam Parameters 
Field 
ID Energy MLC 
Gantry 
Angle 
(deg) 
Collimator 
Angle 
(deg) 
Couch 
Rotation 
(deg) 
Field 
X 
(cm) 
X1 
(cm) 
X2 
(cm) 
Field 
Y 
(cm) 
Y1 
(cm) 
Y2 
(cm) 
SSD 
(cm) MU 
01 
RPO 
200 
6MV Dynamic 200 0 0 11.0 6.0 5.0 14.8 6.5 8.3 87.8 127 
02 
RPO 
240 
6MV Dynamic 240 0 0 8.8 4.5 4.3 14.5 6.5 8.0 85.1 108 
03 
RAO 
280 
6MV Dynamic 280 0 0 11.4 5.6 5.8 14.8 6.5 8.0 84.9 141 
04 
RAO 
320 
6MV Dynamic 320 0 0 13.1 6.3 6.8 14.6 6.3 8.3 85.6 147 
05 
Ant 
0 
6MV Dynamic 0 0 0 11.3 5.3 6.0 14.6 6.3 8.3 85.6 139 
06 
LAO 
35 
6MV Dynamic 35 0 0 10.7 4.9 5.8 14.8 6.3 8.5 82.6 117 
 
 
Figure 3.3 Isodose lines for large field size plan with beams displayed. 
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Table 3.4 Split field size plan beam parameters. 
Split Field Size Plan Beam Parameters 
Field 
ID Energy MLC 
Gantry 
Angle 
(deg) 
Collimator 
Angle 
(deg) 
Couch 
Rotation 
(deg) 
Field 
X 
(cm) 
X1 
(cm) 
X2 
(cm) 
Field 
Y 
(cm) 
Y1 
(cm) 
Y2 
(cm) 
SSD 
(cm) MU 
01 
RPO 
200_0 
6MV Dynamic 200 0 0 9.2 7.5 1.7 15.0 6.5 8.5 86.7 141 
01 
RPO 
200_1 
6MV Dynamic 200 0 0 10.0 2.0 8.0 15.0 6.5 8.5 86.7 107 
02 
RPO 
240 
6MV Dynamic 240 0 0 13.8 4.0 9.8 15.1 6.8 8.3 81.7 179 
03 
RAO 
280_0 
6MV Dynamic 280 0 0 13.1 7.5 5.6 15.1 6.8 8.3 81.9 148 
03 
RAO 
280_1 
6MV Dynamic 280 0 0 6.5 15.1 -1.8 8.3 6.8  8.3 81.9 75 
04 
RAO 
320_0 
6MV Dynamic 320 0 0 9.3 9.9 -0.6 14.8 6.5 8.3 83.9 87 
04 
RAO 
320_1 
6MV Dynamic 320 0 0 12.1 4.4 7.7 14.8 6.5 8.3 83.9 169 
05 
Ant 
0_0 
6MV Dynamic 0 0 0 12.2 8.8 3.4 14.6 6.3 8.3 87.4 122 
05 
Ant 
0_1 
6MV Dynamic 0 0 0 8.6 0.3 8.3 14.6 6.3 8.3 87.4 83 
06 
LAO 
35_0 
6MV Dynamic 35 0 0 6.9 8.8 -1.9 14.6 6.3 8.3 84.1 72 
06 
LAO 
35_1 
6MV Dynamic 35 0 0 14.8 8.2 6.6 14.6 6.3 8.3 84.1 191 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Isodose lines for split field size plan with beams displayed. 
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Linear Accelerator 
 A Varian iX medical linear accelerator with a 120 leaf Millennium MLC was 
used to deliver the QA measurements to a planar MapCHECK phantom at 
normal incidence. A radiation beam with a nominal energy of 6 MV at a dose rate 
of 400 MU/minute was used for all the measurements. The linear accelerator was 
calibrated according to TG-51 by the site physicist. The calibration conditions are 
1 cGy/MU at a depth of 1.6 cm at a source-to-surface distance of 100 cm and a 
field size of 10x10 cm2. The linear accelerator is also equipped with Real-Time 
Position Management (RPM) system. The RPM was used to carry out the gating 
requirements of the study.  
Verification Plan 
 The IMRT QA was performed with a MapCHECK Model 1175 diode array 
and a MotionSIM XY/4D robotic apparatus (Sun Nuclear, Melbourne, FL). In 
order to make a comparison of measured dose verses planned dose, a 
verification plan for each of the beams in the four cases used in this study was 
obtained from the Eclipse treatment-planning computer. A verification plan uses 
the same MUs and beam modulation sequences as the patientʼs treatment plan. 
The only difference is the beams are now calculated on a flat phantom with the 
gantry angle of each beam set to zero degrees (gantry in the upright position). 
This arrangement can be reproduced for the QA measurements with the 
MapCheck. The verification plans for each beam were calculated at a depth of 5 
cm in the water equivalent phantom at a source-to-phantom distance of 95 cm. 
 
54 
The calculated dose distribution for the plane at 5 cm depth is then exported from 
the Eclipse computer for comparison with the MapCHECK measured dose.  
MapCHECK 
 The MapCHECK consist of 445 N-type radiation hardened diodes that are 
in a 22 x 22 cm2  two dimensional array. Each diode has an active area of 0.8 x 
0.8 mm2. The instrument is divided into two sections, the inner array and the 
outer array. The inner array has 221 detectors that are on or within the inner 10 x 
10 cm2 portion of the device. The detectors are spaced on a 10 mm grid. The 
rows of the grid are offset so that the diagonal spacing of the detectors is 7.07 
mm. The outer array has 224 detectors that are placed outside the inner 10 x 10 
cm2 portion of the device. The spacing of these detectors is 20 mm and the offset 
of each row gives a diagonal spacing of 14.14 mm. Figure 3.5 shows the detector 
location and geometry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 MapCHECK detector location and geometry (Sun Nuclear Corp., 
2007) 
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 An array calibration was performed on the MapCHECK according to the 
steps provided in the userʼs manual. The array calibration is a process of 
determining the relative sensitivity differences between the detectors. Correction 
factors are applied to eliminate these differences. This array calibration was 
applied to all of the measurements in this study. The MapCHECK must also be 
calibrated for absolute dose. The absolute dose calibration converts the relative 
dose measured by the device to absolute dose by applying a single calibration 
factor to all of the detectors. For the absolute calibration, the detector plane was 
positioned at 100 cm from the radiation source and the field size was adjusted to 
10 x 10 cm2. Solid water, in the amount of 3 cm, was added to the 2 cm inherent 
buildup of the MapCHECK. This placed the detectors at a depth of 5 cm. A 
calculation with the treatment planning system was done to determine that 104 
MUs were needed to give 100 cGy to the detectors with this setup. After the 
setup and the number of MUs needed was established, the absolute calibration 
was completed according to the steps in the userʼs manual. The absolute 
calibration was verified throughout the data collection and adjusted when 
necessary.  
 The MapCHECK software was used to compare the measured dose to the 
planned dose. The two files were compared using absolute dose percent 
difference and distance to agreement (DTA). The software uses three settings to 
control the pass/fail criteria for the measured points: the percent difference, 
distance, and threshold. The percent difference is the allowed difference between 
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a measured and a planned point doses that share the same coordinates. If the 
difference between the two points does not exceed the allowed percent 
difference, the point passes. The value used for this study was 3%. If the 
difference exceeds the allowed percent difference, the DTA test is carried out. 
The distance is a radius around a measured point. A measured point passes the 
DTA test if a planned point is found that is within the radius that is greater than or 
equal to the measured point and a second planned point is found within the 
radius that is less than or equal to the measured point. The distance used in this 
study was 3 mm. The threshold allows one to exclude detectors that are outside 
the region of interest. The value set for this study was 10%. As a result, all 
detectors with values less than 10% of the maximum dose were removed from 
the statistical values (Sun Nuclear Corp., 2007). 
MotionSim XY/4D 
The MotionSim XY/4D is a hardware and software option for the 
MapCHECK that was used in this study to simulate the breathing cycle and tumor 
motion. The MotionSim XY/4D has a flat, moving platform that supports the 
MapCHECK. The device uses motors to move the MapCHECK in the X and Y 
directions. A separate motor is used to drive the marker block of the Varian RPM 
system to represent the breathing cycle. The device moves the marker block in 
an up and down motion to simulate the actual vertical motion of the marker block 
as if it were on the diaphragm of the patient. Figure 3.6 show the MotionSim 
XY/4D table without the MapCHECK attached. The RPM marker block was 
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attached to the gating surrogate housing, where the vertical motion occurs. The 
MapCHECK was placed on the X-Y platform, where tumor motion in the X-Y 
direction can be simulated. The stationary belt bracket is for other forms of gating 
surrogates used to represent the breathing cycle and was not used in this study.  
 
Figure 3.6 MotionSIM XY/4D table (Sun Nuclear Corp., 2007). 
 The software of the MotionSim XY/4D device allows one to program a 
motion kernel to be used in the IMRT QA. The motion kernel is the 3-D motion of 
the tumor (X,Y,Z), relative to the treatment couch, as a function of time. The 
source used to obtain the motion kernel was the 4-D CT. The coordinate system 
used for this study is shown in figure 3.7 with respect to the gantry of the linear 
accelerator and is known as the IEC 61217 coordinate system. The IEC 61217 
coordinate system is used in all the materials for this study. The gantry of the 
linear accelerator is rotated around the patient to deliver the multiple beams of 
the IMRT plans. Each beam of the plan can see the target motion differently. 
Because the gantry angles are adjusted to zero degrees for the IMRT QA, the 
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motion kernel was adjusted to project the motion to a two-dimensional beamʼs-
eye-view (BEV). This only affects the motion in the X direction for this study. For 
instance, a gantry angle of 90 degrees (lateral position) does not see any motion 
in the X direction and a gantry of zero degrees (upright position) will see the 
whole range of motion in the BEV. Each beam sees all of the motion in the Y 
direction. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 IEC 61217 Coordinate system (Sun Nuclear Corp., 2007). 
 To access the XY/4D software, an icon is available in the MapCHECK 
software. A 4-D tumor trajectory can be modeled by entering X, Y, Z, time (t), and 
gating surrogate (GS) values. The time represents the period of the breathing 
cycle. This value, in seconds, is divided into small increments. An X, Y, and Z 
coordinate value is assigned to each increment of the breathing period to 
represent the location of the tumor with respect to time. The GS value controls 
the vertical motion of the RPM marker block with respect to time and is modeled 
to represent the inhale and exhale segments of the breathing cycle. The motion 
kernel begins at t = 0 and the maximum values of X, Y, Z, and GS. This 
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represents the peak of inspiration. As the time is increased, the values of X, Y, Z, 
and GS decrease until the minimum values of each are reached. This represents 
the full expiration. As t increases further to the final value of the breathing period, 
the X, Y, Z, and GS values increase to their maximum values. The above 
process simulates the tumor motion during a complete breathing cycle and can 
be run in a continuous loop during the QA measurement. For this study, the 
length of the breathing cycle was 3.9 seconds. The GS values were modeled 
over the time to match the breathing pattern obtained from the 4D-CT. Figure 3.8 
shows a screen shot of the XY/4D software. The four boxes in the upper left 
corner show the tumor motion (red line) as seen from the axial, sagittal, coronal, 
and beamʼs eye views. The table on the right shows the X, Y, Z, GS, and t values 
of the tumor trajectory. The plot in the bottom left of the figure shows the position 
of the GS through out the cycle (Sun Nuclear Corp., 2007). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 MotionSim XY/4D tumor trajectory display. 
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Real-Time Position Management 
Varianʼs Real-Time Positioning Management (RPM) system was used to 
trigger the linear accelerator to beam on and off, creating the gated treatment 
used in this study. This is the same system that was used to obtain the 4-D CT 
and was also used during the patientʼs treatments. The marker block that was 
attached to the MotionSim XY/4D table reflects the infrared light emitted from the 
illuminator ring of the tracking camera. Figure 3.9 displays images of the marker 
block and tracking camera used by the RPM system.  
 
Figure 3.9 Images of marker block and tracking camera for the RPM system. 
The extremes of the marker blockʼs vertical motion are used to define the 
inhale and exhale positions of the breathing motion. The phases of the breathing 
cycle are then derived from by the RPM system. The phases that defined the 
gating interval for this study, the period in the respiratory cycle when the beam is 
on, were the 30%-70% phases, which are during expiration.  
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Measurements 
 The gantry of the linear accelerator was set to zero degrees. The 
MotionSim XY/4D was placed on the treatment couch and the device was 
leveled. The marker block of the RPM system was secured to the gating 
surrogate housing and the MapCHECK was mounted to the X-Y platform. The 
table was raised to place the detector plane of the MapCHECK at 100 cm from 
the radiation source. The crosshairs of the MapCHECK were aligned with the 
crosshairs of the linear accelerator. Solid water, in the amount of 3 cm, was 
added to the top the MapCHECK. This additional buildup and the MapCHECKʼs 2 
cm of inherent build supplied the 5 cm of water equivalent material needed to 
match the verification plan setup. Figure 3.10 shows images of the setup. 
 
Figure 3.10 Images of treatment room setup. 
MapCHECK measurements for each beam of the four IMRT plans 
representing various field sizes were acquired using varying amounts of motion in 
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one and two dimensions with the gating interval set between the 30%-70% 
phases. A set of measurements was first collected for the medium field size with 
motion in the Y direction only and no gating. Each plan was then measured with 
no motion under the gating conditions. Motion was then added in the Y only 
direction, the X only direction, and the X and Y direction. For the measurements 
with motion in both the X and Y direction, the amount of motion was given in 
each dimension and results in a trajectory that is equal to the hypotenuse. The 
amount of motion started at 0.5 cm and increased in steps of 0.5 cm for each 
plan until the QA clearly failed. A failed plan was defined as less than 90% of the 
measured points passing the 3% absolute dose difference and 3 mm DTA test 
when compared to the verification plan.  
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4.Results 
 The MapCheck results for the four plans used in this study are presented 
in the following tables, plots, and figures. The measured dose planes from each 
of the beams are compared to the calculated dose planes generated from the 
treatment-planning computer. Each plane is at a water equivalent depth of 5 cm 
and 100 cm from the radiation source. The conditions used to determine a 
passing point was a dose tolerance of 3% and a DTA of 3 mm. A QA result is 
considered acceptable if 90% or more of the measured points meet the above 
passing criteria.  
Non-Gated Results with Motion 
 Table 4.1 and figure 4.1 show the results of a non-gated treatment with 
varying amounts of motion in the Y direction for the medium size fields. The 
results agree with the Task Group 76 suggestion that respiratory management 
techniques for any motion less than 0.5 cm may be unwarranted (Keall et al., 
2006). Poor QA results are recorded for motion greater than 0.5 cm with a 30% 
drop in the number of pass points between 0.5 cm and 1.0 cm of motion. Table 
4.5, presented later in this section, shows acceptable QA results for up to 1.5 cm 
of motion in the Y direction with gated treatments (30%-70%) of the medium field 
size. Figure 4.1 demonstrates the regions of increased (red) and decreased
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 (blue) dose for 1.0 cm Y motion. The failed dose regions appear in the direction 
of the Y motion. 
Table 4.1 QA results for varying amounts of Y motion with no gating. 
Medium Field Size Y Motion No Gating 
 No Motion 0.5 cm 1.0 cm 1.5 cm 
Gantry 
Angle 
# of 
Points 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
01 340° 35 35 100 32 91.4 23 65.7 20 57.1 
02 15° 43 41 95.3 43 100 32 74.4 21 48.8 
03 40° 47 45 95.7 43 91.5 30 63.8 17 36.2 
04 70° 46 44 95.7 40 87.0 27 58.7 20 43.5 
05 110° 39 38 97.4 37 94.9 20 51.3 19 48.7 
06 140° 35 35 100 34 97.1 24 68.6 15 42.9 
Total # 
of 
Points 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Plan 
245 238 97.1 229 93.5 156 63.7 112 45.7 
 
 
 
 
 
 
 
Figure 4.1 Display of dose differences for Medium field sizes/1.0 cm Y motion/no 
gating. 
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Small Field Size 
 Table 4.2 presents the results for the small field size with motion only in 
the Y direction. The gated plan passes with 0.5 cm motion, but fails with motion 
of 1.0 cm and greater.  
Table 4.2 Results for gated small field sizes with Y motion. 
Small Field Size Y Motion Gated 30%-70% 
 No Motion 0.5 cm 1.0 cm 1.5 cm 
Gantry 
Angle 
# of 
Points 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
01 
255° 20 19 95.0 18 90.0 18 90.0 17 85.0 
02 
285° 21 21 100 19 90.5 17 81.0 16 76.2 
03 
320° 21 21 100 19 90.5 17 81.0 14 66.7 
04 0° 21 21 100 20 95.2 19 90.5 16 76.2 
05 35° 18 17 94.4 17 94.4 15 83.3 14 77.8 
Total # of 
Points 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Plan 
101 99 98 93 92.1 86 85.1 77 76.2 
 
 The X motion results in table 4.3 for the small field size show some 
improvement with the 1.0 cm motion compared to the results for the Y motion. 
This is most likely due to the reduced amount of X motion seen in the BEV for the 
gantry angles not equal to zero. Notice that beam 04 0°, with a gantry angle of 
zero degrees, in table 4.3 fails while the remainder of the beams for the plan 
pass with 1.0 cm motion. Although the total number of passing points for this plan 
with 1 cm motion is greater than 90%, beam 04 0° has such a low passing 
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percentage that re-planning this treatment and removing or replacing this beam 
with a different gantry angle may be warranted. 
Table 4.3 Results for gated small field sizes with X motion. 
Small Field Size X Motion Gated 30%-70% 
 No Motion 0.5 cm 1.0 cm 1.5 cm 
Gantry 
Angle 
# of 
Points 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
01 
255° 20 19 95.0 19 95.0 19 95.0 19 95.0 
02 
285° 21 21 100 21 100 20 95.2 21 100 
03 
320° 21 21 100 19 90.5 19 90.5 17 81.0 
04 0° 21 21 100 20 95.2 17 81.0 9 42.9 
05 35° 18 17 94.4 17 94.4 17 94.4 15 83.3 
Total # of 
Points 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Plan 
101 99 98 96 95.0 92 91.1 81 80.2 
 
 Table 4.4 records the results of the small field size with motion in the X 
and Y direction. The plan immediately fails with a 0.5 cm of motion in two 
dimensions. The two beams with gantry angles of only 15 degrees off of lateral 
(01 255° and 02 285°) showed the best results. Again, beam 04 0° was the beam 
with the lowest passing percentage. 
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Table 4.4 Results for gated small field sizes with X and Y motion. 
Small Field Size XY Motion Gated 30%-70% 
 No Motion 0.5 cm 
Gantry 
Angle # of Points 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
01 
255° 20 19 95.0 17 85.0 
02 
285° 21 21 100 17 81.0 
03 
320° 21 21 100 16 76.2 
04 0° 21 21 100 12 57.1 
05 35° 18 17 94.4 13 72.2 
Total # of 
Points 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Plan 
101 99 98 75 74.3 
 
 
Medium Field Size 
 The results for the gated medium field size QA measurements with motion 
in the Y direction are given in table 4.5. The plans pass QA with motion up to 1.5 
cm. This is 1.0 cm more of motion than was acceptable in the small field size 
plan with Y motion. These medium field size results also show a 28.2% drop in 
the passing percentage between the passing plan with 1.5 cm of motion in the Y 
direction and the failing plan with 2.0 cm of motion in the same direction.  
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Table 4.5 Results for gated medium field sizes with Y motion. 
Medium Field Size Y Motion Gated 30%-70% 
 No Motion 0.5 cm 1.0 cm 1.5 cm 2.0 cm 
Gantry 
Angle 
# of 
Points 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
01 
340° 35 35 100 34 97.1 33 94.3 34 97.1 26 74.3 
02 15° 43 41 95.3 42 97.7 41 95.3 41 95.3 31 72.1 
03 40°  47 45 95.7 44 93.6 44 93.6 44 93.6 31 66.0 
04 70° 46 44 95.7 45 97.8 45 97.8 43 93.5 27 58.7 
05 
110° 39 38 97.4 38 97.4 37 94.9 38 97.4 25 64.1 
06 
140° 35 35 100 34 97.1 33 94.3 32 91.4 23 65.7 
Total # 
of 
Points 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Plan 
245 238 97.1 237 96.7 233 95.1 232 94.7 163 66.5 
 
 
 
 Table 4.6 shows the gated IMRT QA measurement results for the medium 
field size with motion in the X direction. The plan passes with motion up to 1.0 
cm. This is equal to the small field size QA results for X motion. The beam that 
shows the lowest passing percentage in each interval of motion is 02 15°. This 
beam sees the most X motion in the BEV. The medium field size Y motion plans 
allowed 0.5 cm more motion than the medium field size X motion. This could be a 
result of higher dose gradients along the sides of the beams as opposed to the 
superior and inferior borders. 
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Table 4.6 Results for gated medium field sizes with X motion. 
Medium Field Size X Motion Gated 30%-70% 
 No Motion 0.5 cm 1.0 cm 1.5 cm 
Gantry 
Angle # of Points 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
01 340° 35 35 100 33 94.3 32 91.4 28 80.0 
02 15° 43 41 95.3 40 93.0 38 88.4 31 72.1 
03 40°  47 45 95.7 43 91.5 43 91.5 38 80.9 
04 70° 46 44 95.7 43 93.5 42 91.3 40 87.0 
05 110° 39 38 97.4 37 94.9 36 92.3 34 87.2 
06 140° 35 35 100 35 100 34 97.1 28 80.0 
Total # of 
Points 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Plan 
245 238 97.1 231 94.3 225 91.8 199 81.2 
 
 
Table 4.7 shows the gated IMRT QA results for the medium field size with 
motion in the X and Y direction. Similar to the small fields size plan, the medium 
field size plan fails immediately when motion is added in two dimensions. Figure 
4.2 shows the MapCHECK analysis for a composite of the medium field size 
beams with 0.5 cm motion in two dimensions. A composite plan is a combination 
of all the beams in the plan. The blue areas on the display represent regions of 
lower dose differences in cGy for the comparison between the measured plan 
and the verification plan. The red regions represent regions of increased dose for 
the QA comparison. The regions of dose differences appear in the direction of 
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the motion. The dose summary at the bottom of the analysis shows the percent 
differences for the failed points and their location in the BEV. Set1 is the 
composite of the measured beams for the medium field size with 0.5 cm motion 
in the X and Y direction. Set2 is the composite of the beam verification plans.  
The summary also shows the radius needed to satisfy the DTA analysis. Four of 
the eight failing points are under 4 mm DTA. One point with a DTA of NA is 
found. This means that no points could be found to satisfy the DTA analysis. 
Hence, if a different standard were utilized when performing the analysis, say 3% 
and 4 mm, the plan would have passed.  
 
Table 4.7 Results for gated medium field sizes with X and Y motion. 
Medium Field Size XY Motion Gated 30%-70% 
 No Motion 0.5 cm 1.0 cm 
Gantry 
Angle 
# of 
Points 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
01 340° 35 35 100 32 91.4 31 88.6 
02 15° 43 41 95.3 37 86.0 32 74.4 
03 40°  47 45 95.7 40 85.1 34 72.3 
04 70° 46 44 95.7 39 84.8 35 76.1 
05 110° 39 38 97.4 33 84.6 28 71.8 
06 140° 35 35 100 28 80.0 22 62.9 
Total # of 
Points 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Plan 
245 238 97.1 209 85.3 182 74.3 
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Figure 4.2 MapCHECK analysis of medium field size with 0.5 cm motion in the 
XY direction including a dose failure summary. 
 
 
Large Field Size 
 Table 4.8 shows the gated IMRT QA results for the large field size with 
motion in the Y direction. The plan passes QA with motion up to 1.0 cm. This is 
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0.5 cm of motion less than the medium field size plan with Y motion. The medium 
and large size plans had nearly equal results for 1.0 cm motion in the Y direction, 
measuring 95.1 % and 95.8% respectively. As the motion is increased to 1.5 cm, 
the large field size plan falls to only an 85.3% passing percentage while the 
medium field size plan remains acceptable at 94.7 %. This may be due to the 
small superior area of the field that is seen in figure 3.3. As the motion is 
increased, the results in this region can mimic the results seen for a small field 
size plan. 
Table 4.8 Results for gated large field sizes with Y motion. 
Large Field Size Y Motion Gated 30%-70% 
 No Motion 0.5 cm 1.0 cm 1.5 cm 2.0 cm 
Gantry 
Angle 
# of 
Points 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
01 
RPO 
200° 
197 192 97.5 184 93.4 187 94.9 168 85.3 150 76.1 
02 
RPO 
240° 
153 152 99.3 151 98.7 148 96.7 132 86.3 116 75.8 
03 
RAO 
280° 
172 170 98.8 167 97.1 165 95.9 141 82.0 122 70.9 
04 
RAO 
320° 
188 185 98.4 185 98.4 179 95.2 154 81.9 130 69.1 
05 
ANT 
0° 
198 195 98.5 192 97.0 188 94.9 168 84.8 148 74.7 
06 
LAO 
35° 
192 191 99.5 187 97.4 187 97.4 175 91.1 155 80.7 
Total # of 
Points 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Plan 
1100 1085 98.6 1066 96.9 1054 95.8 938 85.3 821 74.6 
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 Table 4.9 shows the gated IMRT QA results for the large field size plan 
with motion in the X direction. The plan passes with motion up to 1.0 cm in the X 
direction. This is equal to the accepted motion in the medium field size plan for 
motion in the X direction. Again, the beams with gantry angles equal to or near 
zero or 180 degrees showed the lowest passing percentages. Beam 03 RAO 
280°, which is only 10° off of lateral, held a 98.8% passing percentage for the 
complete range of motion measured in the X direction. 
  
Table 4.9 Results for gated large field sizes with X motion. 
Large Field Size X Motion Gated 30%-70% 
 No Motion 0.5 cm 1.0 cm 1.5 cm 
Gantry 
Angle # of Points 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
01 RPO 
200° 197 192 97.5 187 94.9 176 89.3 139 70.6 
02 RPO 
240° 153 152 99.3 152 99.3 152 99.3 149 97.4 
03 RAO 
280° 172 170 98.8 170 98.8 170 98.8 170 98.8 
04 RAO 
320° 188 185 98.4 181 96.3 171 91.0 153 81.4 
05 ANT 
0° 198 195 98.5 190 96.0 173 87.4 134 67.7 
06 LAO 
35° 192 191 99.5 191 99.5 179 93.2 165 85.9 
Total # of 
Points 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Plan 
1100 1085 98.6 1071 97.4 1021 92.8 910 82.7 
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Table 4.10 shows the gated IMRT QA results for the large field size with 
motion in the X and Y direction. The plan passes with 0.5 cm of motion in two 
dimensions. This is an improvement over the results for the small and medium 
field size plans, where both failed with 0.5 cm of motion in two dimensions. 
Figure 4.3 shows the dose distribution of the composite verification plan (set 2) 
and a composite of the measured beams for the large field size with 0.5 cm 
motion in the X and Y direction (set 1). The small high dose areas in the center of 
the verification plan in set 2 (280 cGy) become blurred and increase in size as 
the 0.5 cm motion is applied to the measured beams in set 2. Other dose 
gradients are also smeared or blurred due to the motion.   
Table 4.10 Results for gated large field sizes with X and Y motion. 
Large Field Size XY Motion Gated 30%-70% 
 No Motion 0.5 cm 1.0 cm 
Gantry 
Angle 
# of 
Points 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
01 
RPO 
200° 
197 192 97.5 171 86.8 152 77.2 
02 
RPO 
240° 
153 152 99.3 149 97.4 146 95.4 
03 
RAO 
280° 
172 170 98.8 159 92.4 155 90.1 
04 
RAO 
320° 
188 185 98.4 177 94.1 149 79.3 
05 
ANT 
0° 
198 195 98.5 172 86.9 146 73.7 
06 
LAO 
35° 
192 191 99.5 180 93.8 161 83.9 
Total # of 
Points 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Plan 
1100 1085 98.6 1008 91.6 909 82.6 
 
 
75 
 
Figure 4.3 Composite dose of measured beams (Set1) and composite dose of 
verification plan beams (Set2) for 0.5 cm motion in the X and Y direction for the 
large field size plan. 
 
 
Split Field Size 
 Figure 4.11 shows the gated IMRT QA results for the split field size plan 
with motion in the Y direction. The plan passes with motion up to 1.0 cm in the Y 
direction. This compares with the amount of motion that was acceptable for the 
large field size plan with motion in the Y direction. Again, a small area of the field 
is positioned superior to the main body of the tumor, seen in figure 3.4, and may 
be the cause of the poor results. A wide range of field sizes make up the split 
field size plan, as the large beams are split into subfields when necessary to 
account for the limits of the MLCs.  
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Table 4.11 Results for gated split field sizes with Y motion. 
Split Fields Y Motion Gated 30%-70% 
 No Motion 0.5 cm 1.0 cm 1.5 cm 2.0 cm 
Gantry 
Angle # of Points 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
01 
RPO 
200°_0 
102 100 98.0 99 97.1 94 92.2 92 90.2 77 75.5 
01 
RPO 
200°_1 
156 155 99.4 155 99.4 155 99.4 138 88.5 116 74.4 
02 
RPO 
240° 
188 186 98.9 186 98.9 184 97.9 159 84.6 141 75.0 
03 
RAO 
280°_0 
189 187 98.9 184 97.4 178 94.2 148 78.3 121 64.0 
03 
RAO 
280°_1 
30 30 100.0 28 93.3 28 93.3 25 83.3 22 73.3 
04 
RAO 
320°_0 
92 92 100.0 92 100 91 98.9 86 93.5 75 81.5 
04 
RAO 
320°_1 
156 153 98.1 153 98.1 150 96.2 131 84.0 120 76.9 
05 
Ant 
0°_0 
154 151 98.1 150 97.4 147 95.5 127 82.5 110 71.4 
05 
Ant 
0°_1 
26 26 100 25 96.2 26 100 20 76.9 17 65.4 
06 
LAO 
35°_0 
48 48 100 48 100 47 97.9 41 85.4 40 83.3 
06 
LAO 
35°_1 
202 197 97.5 195 96.5 192 95.0 182 90.1 159 78.7 
Total # of 
Points 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Plan 
1343 1325 98.7 1315 97.9 1292 96.2 1149 85.6 998 74.3 
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Table 4.12 shows the gated IMRT QA results for the split field size with 
motion in the X direction. The plan passes with motion up to 1.0 cm in the X 
direction. This motion limit of 1.0 cm compares with other field sizes investigated 
in this study with motion in the X direction.  
 
Table 4.12 Results for gated split field sizes with X motion. 
Split Fields X Motion Gated 30%-70% 
 No Motion 0.5 cm 1.0 cm 1.5 cm 
Gantry 
Angle # of Points 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
Passing 
Points 
Passing 
Percent 
01 
RPO 
200°_0 
102 100 98.0 97 95.1 99 97.1 78 76.5 
01 
RPO 
200°_1 
156 155 99.4 150 96.2 136 87.2 91 58.3 
02 
RPO 
240° 
188 186 98.9 186 98.9 185 98.4 180 95.7 
03 
RAO 
280°_0 
189 187 98.9 184 97.4 183 96.8 183 96.8 
03 
RAO 
280°_1 
30 30 100.0 30 100 30 100 30 100 
04 
RAO 
320°_0 
92 92 100.0 92 100 90 97.8 86 93.5 
04 
RAO 
320°_1 
156 153 98.1 149 95.5 143 91.7 125 80.1 
05 
Ant 
0°_0 
154 151 98.1 153 99.4 142 92.2 115 74.7 
05 
Ant 
0°_1 
26 26 100 26 100 24 92.3 19 73.1 
06 
LAO 
35°_0 
48 48 100 48 100 48 100 46 95.8 
06 
LAO 
35°_1 
202 197 97.5 187 92.6 183 90.6 159 78.7 
Total # of 
Points 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Total 
Passing 
Points 
Plan 
Percent 
Passing 
Plan 
1343 1325 98.7 1302 96.9 1263 94.0 1112 82.8 
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Table 4.13 shows the gated IMRT QA results for the split field size with 
motion in the X and Y direction. The plan passes with up to 0.5 cm of motion in 
the X and Y direction. This matches the amount of motion allowed for the large 
field size plan with motion in the X and Y direction. 
Table 4.13 Results for gated split field sizes with X and Y motion. 
Split Fields XY Motion Gated 30%-70% 
 No Motion 0.5 cm 1.0 cm 
Gantry Angle # of Points Passing Points Passing Percent Passing Points 
Passing 
Percent Passing Points 
Passing 
Percent 
01 
RPO 
200°_0 
102 100 98.0 98 96.1 95 93.1 
01 
RPO 
200°_1 
156 155 99.4 145 92.9 126 80.8 
02 
RPO 
240° 
188 186 98.9 178 94.7 167 88.8 
03 
RAO 
280°_0 
189 187 98.9 178 94.2 170 89.9 
03 
RAO 
280°_1 
30 30 100.0 28 93.3 29 96.7 
04 
RAO 
320°_0 
92 92 100.0 92 100 86 93.5 
04 
RAO 
320°_1 
156 153 98.1 149 95.5 133 85.3 
05 
Ant 
0°_0 
154 151 98.1 143 92.9 127 82.5 
05 
Ant 
0°_1 
26 26 100 24 92.3 20 76.9 
06 
LAO 
35°_0 
48 48 100 48 100 45 93.8 
06 
LAO 
35°_1 
202 197 97.5 188 93.1 173 85.6 
Total # of 
Points 
Total Passing 
Points 
Plan Percent 
Passing 
Total Passing 
Points 
Plan Percent 
Passing 
Total Passing 
Points 
Plan Percent 
Passing 
Plan 
1343 1325 98.7 1271 94.6 1171 87.2 
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The QA results for the split field size plan with 1.5 cm of motion in two 
dimensions fall just under the 90% limit set for an acceptable plan with 87.2% of 
the total points meeting the 3%/3 mm criterion. Figure 4.4 shows the measured 
dose composite for the split field size plan with 1.0 cm motion in the X and Y 
dimensions (Set1) along with the composite dose of the verification plan for the 
same field size (Set2). Blurring of the dose distribution can be seen causing the 
dose colors, which are separated by 31 cGy, to increase in some regions and 
disappear in others. This can have a large impact on a treatment of several 
fractions.  
 
Figure 4.4 Composite dose of measured beams (Set1) and composite dose of 
verification plan beams (Set2) for 1.0 cm motion in the X and Y direction for the 
split field size plan. 
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Discussion 
 IMRT treatments for lung cancer are subject to intrafraction motion caused 
by the patientʼs breathing cycle. This motion, depending on its magnitude, can 
introduce unacceptable alterations in the desired dose distribution. A gated 
radiation treatment is a solution to this problem without increasing the margins 
around the tumor. Because residual motion will still exist during a gated 
treatment, there are limits on the magnitude of the motion.  
 The AAPM Task Group Report 76 recommends a respiratory management 
technique, such as gating, for any motion greater than 0.5 cm. The IMRT QA 
results for the medium field size plan with no gating, shown in table 4.1, support 
this recommendation. The same table can be compared with the IMRT QA 
results for the medium field size plan with gating, shown in table 4.5, to validate 
the importance of using a gated treatment with motion greater than 0.5 cm. 
 To reduce the time wasted in a clinic on creating IMRT lung plans that 
may fail QA, this study investigated the amount of tumor motion that can be 
accepted with a gating window of 30% to 70%. A previous study by Chen et al. 
investigated gated IMRT lung QA with motion up to 3 cm in the longitudinal or Y 
direction. That study only looked at one IMRT plan and used several different 
sized gating windows. The conclusion of that study was that the residual motion 
should be limited to 0.5 cm (Chen et al., 2009). The medium, large, and split field
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 size plans with motion in the Y direction measured for this paper agree with 
Chenʼs conclusion on residual motion. Each of the previously mentioned plans 
passed the IMRT QA with 0.4 cm to 0.6 cm of residual motion in the Y direction 
(40% of the tumor motion in the Y direction). The small field size plan measured 
in this study only permitted 0.2 cm of residual motion in the Y direction.  
  The gated IMRT QA results were expected to allow for a larger magnitude 
of motion in the X direction because of the reduced amount of motion seen in the 
BEV for a majority of the beams used in the IMRT plans. Although this effect 
could be seen in the individual beam evaluations, the total plan results were 
similar to the motion in the Y direction. The only improvement was the small field 
size plan which passed with 1.0 cm of motion in the X direction and only 0.5 cm 
of motion in the Y direction. The reason for the unexpected results could be 
because an IMRT plan attempts to avoid giving large amounts of dose to nearby 
critical structures. Because of this, the dose gradients are steeper at the side 
borders of the fields as opposed to the superior or inferior borders of the field. 
During beam selection for an IMRT plan with known motion in the X direction, it is 
best to avoid beams with gantry angles equal to or near 0° and 180° when 
possible to take advantage of the reduced motion seen in the BEV.  
  For the motion in two dimensions, the magnitude of the motion trajectory 
is equal to the hypotenuse of the right triangle formed from the X and Y motion. 
This motion is at a maximum when the X and Y values for motion are equal and 
only occurs when the gantry is at an angle of 0° or 180°. For the IMRT QA results 
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with 0.5 cm of motion in the X and Y direction, the maximum amount of motion 
seen by any beam was 0.707 mm. This gives a maximum value for the residual 
motion of 0.28 cm (40% of tumor motion) for the gated interval used in this study. 
Although larger amounts of residual motion was accepted in previous 
measurements for motion in one dimension, the QA was not as successful for 
motion in two dimension. Only the large and split field size plans passed with 
tumor motion of 0.5 cm in the X and Y direction.  
 The results of this study can be used as a baseline for determining if a 
gated IMRT QA will pass under the same conditions set in this study. The goal is 
to determine in advance the need to adjust one or more of the many parameters 
that make up a respiratory-gated IMRT plan. The options can include changing to 
a smaller gating window, increasing the dose rate, increasing the tumor margin, 
or changes in beam gantry angles. These adjustments can have a negative effect 
on the patientʼs treatment. A smaller gating window will require longer treatment 
times and could introduce patient motion. An increase in the dose rate can 
reduce the time needed to deliver a gated treatment, but can also introduce 
errors in the MLCʼs delivery of the fluence (Khan, 2007). Increasing the tumor 
margin can lead to higher doses for the normal tissue. 
 Table 5.1 gives a summary of the gated IMRT QA results for the 
measurements taken in this study. The average equivalent field size for each 
plan was calculated to allow users to properly reference the correct plan. The 
equivalent square for each field size was found by using (4 x the area)/ perimeter 
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(Khan, 2010). Because the split field size plan is made up of large fields split into 
subfields, the equivalent square field size was not calculated for this plan. The 
results are given in a simple pass or fail using the 3% /3 mm condition explained 
earlier.  
Table 5.1 Summary of Gated IMRT QA results for this study. 
Gated (30%-70%) IMRT QA Results (400 MU/min) 
Y Motion (cm) X Motion (cm) XY Motion (cm) 
Plan 
ID 
Eq. 
Square 
(cm2) 0.5 1.0 1.5 0.5 1.0 1.5 0.5 1.0 1.5 
Small 3.4 Pass Fail Fail Pass Pass Fail Fail Fail Fail 
Medium 4.9 Pass Pass Pass Pass Pass Fail Fail Fail Fail 
Large 12.5 Pass Pass Fail Pass Pass Fail Pass Fail Fail 
Split NA Pass Pass Fail Pass Pass Fail Pass Fail Fail 
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Conclusion 
 Lung IMRT plans are improved with the use of a respiratory gating system. 
Acceptable IMRT QA results can be achieved with up to 1.0 cm of motion in the 
Y direction for plans with an average equivalent square field size greater than or 
equal to 4.9 cm2. Larger field sizes may have produced better results if the tumor 
shape used in this study was more uniform and did not contain small areas 
extending from the main body of the tumor. Smaller gated field sizes can 
successfully pass IMRT QA with 0.5 cm of motion in the Y direction. Acceptable 
gated IMRT QA plans can be acquired with up to 1.0 cm of motion in the X 
direction and is independent of field size. IMRT plans with field sizes greater than 
12.5 cm2 are required to pass gated IMRT QA with 0.5 cm of motion in the X and 
Y direction.  
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